Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantheus HoldingsLNTH -0.27%80 Equity-to-Asset is 0.54 as of Jun. 2026, which is 10% above its 10-year median of 0.49. GuruFocus rates LNTH with a GF Score™ of 80/100 and a GF Value™ of $91.52 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Lantheus Holdings ranks worse than 60.1% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lantheus Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $1,312 Mil. Lantheus Holdings's Total Assets for the quarter that ended in Jun. 2026 was $2,415 Mil.
Therefore, Lantheus Holdings's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.54.
The historical rank and industry rank for Lantheus Holdings's Equity-to-Asset or its related term are showing as below:
LNTH'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.48 Med: 0.49 Max: 0.63
Current: 0.54
During the past 13 years, the highest Equity to Asset Ratio of Lantheus Holdings was 0.63. The lowest was -0.48. And the median was 0.49.
LNTH's Equity-to-Asset is ranked worse than 60.1% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs LNTH: 0.54
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Lantheus Holdings Equity-to-Asset Related Terms
Lantheus Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LNTH vs HIMS, LQDA, AMRX: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Lantheus Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a Equity-to-Asset of 0.54 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lantheus Holdings and its competitors. This is 10% above median its historical median of 0.49. According to the industry distribution chart, Lantheus Holdings ranks #604 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 60.1%.
Is Lantheus Holdings' Equity-to-Asset too high?
Lantheus Holdings' current Equity-to-Asset of 0.54 is 10% above median its 10-year median of 0.49. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Lantheus Holdings' value of 0.54 is 11.5% below this industry median. Based on the distribution chart, Lantheus Holdings ranks #604 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lantheus Holdings has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Equity-to-Asset compare to HIMS and LQDA?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #604 out of 1005 companies for Equity-to-Asset. This places Lantheus Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Lantheus Holdings' value of 0.54 is 11.5% below this benchmark. While the company's 10-year median is 0.49 vs. the industry median of 0.61, Lantheus Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current Equity-to-Asset of 0.54 is 11.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current Equity-to-Asset is 0.54, which is 10% above median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Fairly Valued. The stock's GF Value™ is $91.52, compared to a current price of $99.97 — trading 9.2% above its estimated fair value. The current Equity-to-Asset is 0.54, which is 10% above median its 10-year median of 0.49 and 11.5% below the Drug Manufacturers industry median of 0.61. Lantheus Holdings' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Equity-to-Asset is 0.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $99.97 is trading 9.2% above its estimated GF Value™ of $91.52.
GuruFocus considers Lantheus Holdings to be Fairly Valued.
Key valuation signals for LNTH:
Equity-to-Asset: 0.54 (10% above median its 10-year median of 0.49)
GF Value™: $91.52 vs. price of $99.97 (9.2% above fair value)
Industry Position: 11.5% below the Drug Manufacturers median (#604 of 1005)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
80GF Score
Get the complete analysis for LNTH
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
